Headache: Treatment update [PDF]
eNeurologicalSci, 2022 Primary headache disorders in particular migraine are one of the most common causes of disability worldwide. Given the high burden of migraine in terms of disability, there has been an effort to develop migraine specific therapies that has led to the ...
Oyindamola I. Ogunlaja, Peter J. Goadsby
doaj +3 more sources
The history and rationale of the development of new drugs for migraine treatment [PDF]
Arquivos de Neuro-Psiquiatria, 2023 Migraine is one of the most prevalent and disabling diseases in the world. Migraine attack treatments and prophylactic treatments of this disease are essential to lessen its individual, social, and economic impact.
Pedro André Kowacs +3 more
doaj +3 more sources
The Ditans, a New Class for Acute Migraine: Minireview
Journal of Current Research in Scientific Medicine, 2020 Lasmiditan (LDT), a new drug, was approved by the Food and Drug Administration in October 2019 for acute migraines with or without aura. LDT belongs to a new class of drugs “-ditans,” in which the mechanism is different from the triptans since it does ...
Jamir Pitton Rissardo
exaly +4 more sources
Medication-Overuse Headache: Update on Management [PDF]
LifeLong-term frequent use of acute pain medication for the treatment of headaches has paradoxically been shown to increase the frequency of headaches. So-called medication-overuse headache (MOH) is particularly problematic in patients with migraine who ...
Prut Koonalintip +2 more
doaj +4 more sources
Migraine: Epidemiology, Risk Factors, Pathophysiology, and Treatment [PDF]
MedCommMigraine is a common, disabling brain disorder that affects about 1 billion people worldwide and disproportionately burdens women and working‐age adults.
Weiwei Lu +9 more
doaj +3 more sources
Knowledge, Attitude, and Practices of General Neurologists and Headache Experts Toward Migraine Treatment: A Cross-Sectional Study in India [PDF]
Annals of Indian Academy of NeurologyBackground and Objectives: Migraine, a disabling neurological disorder, poses a significant global burden, especially among women of reproductive age.
Sanjith Aaron +3 more
doaj +2 more sources
Trends in utilization and costs of migraine medications, 2017–2020 [PDF]
The Journal of Headache and Pain, 2022 Objective This study examines changes in utilization and costs trends associated with migraine medications. Background Migraine attacks are a burden to many patients.
Jennifer L. Nguyen +6 more
doaj +2 more sources
Emerging pharmacological targets in migraine therapy: CGRP and beyond [PDF]
Frontiers in PharmacologyMigraine is a prevalent, complex, and disabling neurological disorder. Available treatments consist of repurposed drugs, with medication switching and treatment failure a common occurrence.
D. Atraszkiewicz, D. Dahiya
doaj +2 more sources
Healthcare service provided for headache patients in selected African countries: a cross-sectional survey of clinician perspectives [PDF]
Frontiers in NeurologyBackgroundHeadache disorders represent a major global health burden that is highly prevalent across the continent of Africa; however, they remain underdiagnosed and inadequately managed.
Amr Hassan +28 more
doaj +2 more sources
Treatment patterns of patients with migraine eligible for anti-CGRP pathway monoclonal antibodies [PDF]
Frontiers in NeurologyIntroductionMigraine is a debilitating neurological disorder, with a wide range of symptoms and disease burden, underscoring the heterogeneity of patients’ disease characteristics and treatment needs.
Ani C. Khodavirdi +9 more
doaj +2 more sources